Beverly, Massachusetts-based Cellceutix Corporation (OTCBB: CTIX) reported this morning that they have chosen Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) to synthesize and manufacture Prurisol, Cellceutix’s lead anti-psoriasis drug candidate.  Cellceutix will be advancing Prurisol into Phase II/III clinical trials under guidance from the Food and Drug Administration that the drug qualifies for a 505(b)(2) designation. Read More

Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, reports today that it has participated in a meeting with the U.S. Food and Drug Administration (“FDA”) pertaining to the Company’s psoriasis compound, Prurisol™.  As previously disclosed on April 16, 2012, the Company had Read More

This one day might be the story called “The Little Biotech That Could”.  Cellceutix Corp. (OTCBB: CTIX) has a pipeline of eight drugs with three that have already begun clinical trials (one for cancer, one for psoriasis and one for autism).   The flagship drug, Kevetrin™ is being developed as an anti-cancer drug with clinical trials slated to be hosted at the vaunted Dana-Farber Cancer Center. Read More